Valneva Shares Surge 5.5% at Close Following Promising Results
Valneva's stock closed on Thursday, November 27 at 4.30 euros, up by 5.5% from the previous day. This surge followed the announcement on Wednesday of positive final Phase 2 results for its Lyme disease vaccine candidate, developed in partnership with Pfizer. The traded volumes accounted for 0.78% of the capital, while the CAC 40 saw a marginal increase of 0.04% to 8,099.47 points.
Positive Final Data Announced for Phase 2 Lyme Disease Vaccine Candidate
Valneva announced on November 26 positive final immunogenicity and safety data for the Phase 2 study VLA15-221 of its Lyme disease vaccine candidate VLA15. The results demonstrated a strong anamnestic immune response and a favorable safety profile six months after a third booster dose across all age groups. This announcement comes at a favorable time for the French biotech: the stock has now increased by 15.1% over a week and 127.3% over a year, significantly outperforming the CAC 40, which gained 12.58% over the same annual period. Currently, there is no human vaccine against Lyme disease, and VLA15 is the most advanced vaccine candidate against this disease, with two ongoing Phase 3 trials. The U.S. Centers for Disease Control and Prevention estimate that about 476,000 people are diagnosed and treated for Lyme disease each year in the United States and 132,000 cases are reported annually in Europe. Subject to positive Phase 3 data, Pfizer plans to submit marketing authorization applications to the FDA and the European Medicines Agency in 2026. The prospect of potential commercialization of the vaccine in 2026 fuels investor optimism.
Technical Indicators Show Bullish Signals
Technically, the stock is now trading above its 50-day moving average set at 4.20 euros, a bullish signal confirming the positive trend initiated in recent weeks. The RSI stands at 64, in a zone of positive dynamics without reaching the overbought zone, suggesting that a continued rise is possible in the short term. The stock's volatility remains high with a one-month indicator at 11.62, characteristic of biotechnological values subject to clinical and regulatory uncertainties. The MACD displays an encouraging signal with a positive histogram at 0.04, indicating the beginning of a bullish divergence between the MACD line and its signal line. The price is also moving above the lower Bollinger band set at 3.63 euros, gradually approaching the resistance threshold at 4.45 euros. A breakout of this level could pave the way for a continuation of the upward movement, although the presence of a net short position representing about 0.60% of the capital signals persistent caution among some market players.
Mixed Operational Context for the Franco-Austrian Laboratory
The operational context remains mixed for the Franco-Austrian laboratory. The group reported a revenue of 127 million euros over nine months, in an environment marked by the immediate suspension by the U.S. FDA of the license for IXCHIQ, its chikungunya vaccine, which entails a halt to shipments and sales in the United States. This vaccine contributed 7.5 million euros to total sales in the first half of 2025. Despite this setback, movements of executives reveal a mixed sentiment with a purchase of 3,750 shares for about 14,927 euros, against three sales representing 18,380 shares for 82,129 euros. The quarterly performance remains solid with a 12.68% increase over three months. Investors are now betting on the commercial potential of VLA15, whose clinical data strengthen its credibility in the race towards the first approved vaccine against Lyme disease, a market estimated at several hundred million euros annually in North America and Europe.
